Treatment of Angiotensin Peptide (1-7) for COVID-19

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 25, 2020

Primary Completion Date

August 31, 2020

Study Completion Date

September 30, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

Biological/Vaccine: Angiotensin peptide (1-7) derived plasma

angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants

Trial Locations (1)

34303

Kanuni Sultan Suleyman Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Kanuni Sultan Suleyman Training and Research Hospital

OTHER

NCT04375124 - Treatment of Angiotensin Peptide (1-7) for COVID-19 | Biotech Hunter | Biotech Hunter